CAR T therapies in multiple myeloma: Unleashing the future
M Sheykhhasan, A Ahmadieh-Yazdi… - Cancer Gene …, 2024 - nature.com
In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that
have revolutionized the landscape of care for cancer patients. While traditional pillars such …
have revolutionized the landscape of care for cancer patients. While traditional pillars such …
Cancer biomarkers for targeted therapy
D Liu - Biomarker research, 2019 - Springer
Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer
therapies. Antibody-based agents targeting the cancer biomarkers include monoclonal …
therapies. Antibody-based agents targeting the cancer biomarkers include monoclonal …
Immunotherapy in AL amyloidosis
Y Zhang, RL Comenzo - Current Treatment Options in Oncology, 2022 - Springer
Opinion Statement Light-chain amyloidosis is a rare disorder where a small clone of plasma
cells is producing excess toxic light chains that deposit in various organs and cause …
cells is producing excess toxic light chains that deposit in various organs and cause …
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
C Ambrose, L Su, L Wu, FJ Dufort, T Sanford, A Birt… - PLoS …, 2021 - journals.plos.org
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T
cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here …
cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here …
CD19-targeting CAR T cells potently redirected to kill solid tumor cells
C Ambrose, L Su, L Wu, F Dufort, T Sanford, A Birt… - bioRxiv, 2020 - biorxiv.org
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T
cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here …
cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here …